MZ-101
Based on 4 publication(s) in Google Scholar
MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.42%
- CAS No.: 2839908-40-4
- 화학식: C25H28FN5O2
- 분자량:449.52
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MZ-101
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
-
IHC
-
WB
Biological Activity
MZ-101 (0.001-100 μM, 7 days) inhibits glycogen synthesis and reduces glycogen accumulation in fibroblasts expressing GYS1 [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57Bl6 mice between 7 and 10 weeks old and male Pompe mice between 10 and 32 weeks old[2]
-
Dosage:2-200 mg/kg
-
Administration:p.o., a single dose for 5 h
-
Result:Reduced incorporation of glucose into glycogen in skeletal and cardiac muscles of both WT and GAA KO mice in a dose-dependent manner.
Chemical Information
-
CAS No. 2839908-40-4
-
Appearance Solid
-
분자량 449.52
-
화학식 C25H28FN5O2
-
Color Off-white to light yellow
-
SMILES
O=C([C@H]1N(C[C@@H](C1)F)C(CC2=CN=NN2)=O)N[C@@H](C3=CC=CC=C3)C4=CC=C(C=C4)C(C)C
-
Synonyms
GYS1-IN-2
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Rep
Blocking glycogen synthase 1 in white adipose tissue alleviates hypermetabolism following severe burn injury through inhibition of JAK2 by UDPG. [Abstract]2025 Nov 18;44(12):116577. PMID: 41259203
MZ-101 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 18;44(12):116577. [Abstract]
MZ-101 (15 mg/kg; PO; 7 days) led to an increase in UDPG levels in iWAT in Third-degree burn models in 8-week-old male C57BL/6J mice.
MZ-101 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 18;44(12):116577. [Abstract]
MZ-101 (15 mg/kg; PO; 7 days) reduced the burn-induced elevation of abdominal iWAT temperature in Third-degree burn models in 8-week-old male C57BL/6J mice.
MZ-101 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 18;44(12):116577. [Abstract]
MZ-101 (15 mg/kg; PO; 7 days) reduced the levels of UCP1 protein as well as the phosphorylation of JAK2 and STAT3 in iWAT tissue in Third-degree burn models in 8-week-old male C57BL/6J mice.
MZ-101 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 18;44(12):116577. [Abstract]
MZ-101 (15 mg/kg; PO; 7 days) indicated a reduction in UCP1 in iWAT and significantly reduced the number of adipocytes, which were smaller and multinucleated in iWAT at Third-degree burn model in 8-week-old male C57BL/6J mice.
MZ-101 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 18;44(12):116577. [Abstract]
MZ-101 (15 mg/kg; PO; 7 days) decreased the protein levels of ATGL and phosphorylated HSL in both iWAT and eWAT at Third-degree burn model in 8-week-old male C57BL/6J mice.
-
Brain Behav Immun
STK40 contributes to neuropathic pain by modulating macrophagic glycogen metabolism and inflammatory responses through the AKT/GSK3β/GYS1 axis. [Abstract]2026 Jun 22:137:106877. PMID: 42331299 -
bioRxiv
Quantifying Glycogen and Lipid Droplet Synthesis in Ovarian and Cervical Cancer Cells using Deuterated Raman Probes with Stimulated Raman Scattering Microscopy. [Abstract]2026 Mar 18:2026.03.16.712189. PMID: 41890088
용액&용해도
DMSO : 100 mg/mL (222.46 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.12 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (11.12 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[2]. Ullman JC, et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med. 2024 Jan 17;16(730):eadf1691. [Content Brief]
[3]. Gaspar RC, et al. Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease. Am J Physiol Endocrinol Metab. 2024 Oct 1;327(4):E524-E532. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2246 mL | 11.1230 mL | 22.2460 mL | 55.6149 mL |
| 5 mM | 0.4449 mL | 2.2246 mL | 4.4492 mL | 11.1230 mL | |
| 10 mM | 0.2225 mL | 1.1123 mL | 2.2246 mL | 5.5615 mL | |
| 15 mM | 0.1483 mL | 0.7415 mL | 1.4831 mL | 3.7077 mL | |
| 20 mM | 0.1112 mL | 0.5561 mL | 1.1123 mL | 2.7807 mL | |
| 25 mM | 0.0890 mL | 0.4449 mL | 0.8898 mL | 2.2246 mL | |
| 30 mM | 0.0742 mL | 0.3708 mL | 0.7415 mL | 1.8538 mL | |
| 40 mM | 0.0556 mL | 0.2781 mL | 0.5561 mL | 1.3904 mL | |
| 50 mM | 0.0445 mL | 0.2225 mL | 0.4449 mL | 1.1123 mL | |
| 60 mM | 0.0371 mL | 0.1854 mL | 0.3708 mL | 0.9269 mL | |
| 80 mM | 0.0278 mL | 0.1390 mL | 0.2781 mL | 0.6952 mL | |
| 100 mM | 0.0222 mL | 0.1112 mL | 0.2225 mL | 0.5561 mL |
MZ-101 Related Classifications
HY-157646 Related Classifications
Powered by Bioz